RSS

antibody drug conjugates (ADCs)

A partnership agreement has been signed by specialist antibody drug conjugate (ADC) contract services company, ADC Biotechnology, and multi-disciplined engineering specialists, WHP, for construction of a dedicated bioconjugation facility. more

News

Global provider of advanced delivery technologies and development solutions, Catalent, and clinical-stage biotechnology company, Vaccinex, have signed an agreement for the development of an antibody drug conjugate (ADC) to be used against cancer more

News

Experts from biotech company ADC Biotechnology, have issued a warning that poor aggregation will cause problems in the antibody-drug conjugate (ADC) pipeline, with millions being wasted in development costs. more

News

The Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline (GSK) for its investigational B-cell mutation agent (BCMA) monoclonal antibody-drug conjugate, for relapsed and refractory multiple myeloma more

News

Biotechnology company, GamaMabs Pharma, and the global biologics R&D arm of AstraZeneca, MedImmune, have entered into a licensing agreement for the development of an antibody drug conjugate (ADC) to target cancer. more

News

The antibody drug conjugate (ADC) development company, Glythera, has been granted exclusive, worldwide rights to Cancer Research UK’s novel CDK11 inhibitor programme for the development of multiple ADCs. more

News

Demand for high potent active pharmaceutical ingredients is driving the need for high potency handling capabilities. Here, Mike Avraam, global product manager for ChargePoint PharmaSafe, ChargePoint Technology, discusses this growing sector in detail more

Opinion

ADC Biotechnology has secured investment for an $11 million bioconjugation facility, to be constructed at its new site in Deeside, North Wales, UK. more

News

Biopharmaceutical companies, AbbVie and Bristol-Myers Squibb, have announced the formation of a clinical research collaboration to evaluate a combination therapeutic regimen for the treatment of advanced solid tumours. more

News

Clinical-stage biotechnology company, Visterra, has been awarded a research and development contract from the public-private partnership, Combating Antibiotic Resistant Bacteria Accelerator (CARB-X). more

News

Sylvain Querol (MEng), tendering manager, Europe, at Powder Systems Limited on how to achieve high containment for HPAPI small-scale production. more

News

Michal Wlodarski, Camin examines the manufacturing challenge of antibody-drug conjugates more

Opinion

Jennifer Mitcham, Catalent Biologics, offers insight into the new generation of antibody drug conjugates and the increasing importance biologics play in the fight against disease more

Opinion

A fully integrated antibody drug conjugate (ADC) facility is to be built at Novasep's Le Mans site in France, complementing the company's current ADC offering with full bioconjugation services to meet increasing market demand. more

News

Sigma-Aldrich Corporation has announced that SAFC Commercial, its custom manufacturing services business unit, has completed the expansion of its St. Louis facility to support commercial-scale ADC manufacturing. more

News

Contract testing organisation BioOutsource has amplified its position as a global leader in antibody drug conjugates (ADC) characterisation and announced a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon... more

Technology

To meet rising demand for high potency active pharmaceutical ingredients (HPAPIs) spurred by the growing targeted therapy approach in the treatment of diseases, in particular oncology, Switzerland-based CARBOGEN AMCIS has completed a capital... more

Technology

Sigma-Aldrich Corporation’s custom manufacturing services business unit, SAFC Commercial (www.sigma-aldrich.com/safc), is expanding two of its manufacturing facilities in the US to support drug manufacturers in efficiently bringing new targeted... more

Technology